USFDA issued a warning letter to Glenmark Pharmaceuticals for significant CGMP violations at its Pithampur plant, including failing to establish laboratory controls and adequate testing programs.

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing ...

Glenmark Pharmaceuticals share price surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

The US health regulator has pulled up Glenmark Pharmaceuticals for manufacturing lapses, including failure to establish laboratory controls, at its Pithampur-based plant.      In a warning letter, the ...

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

Glenmark Pharma shares hit upper circuit limit after signing a USD 2 billion deal with AbbVie for a cancer drug. Stock hits ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, ...